Search results
Showing 8506 to 8520 of 8904 results
May 2022: This guidance has been withdrawn. For the latest guidance, see the UK Kidney Association’s recommendations for minimising the risk of transmission of COVID-19 in adult haemodialysis units. See also NICE's guideline on managing COVID-19.
This guidance has been updated and replaced by HealthTech guidance 639.
This guidance has been updated and replaced by NICE HealthTech guidance 643.
Pneumonia (community-acquired): antimicrobial prescribing (NG138)
This guideline has been updated and replaced by NICE's guideline on pneumonia in adults: diagnosis and management (NG250).
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or recently pregnant people (NG255).
We have moved NG251 to become a 'NICE Review'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The review itself has not changed. See NICE review 1 on DMD Care UK’s guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations.
Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)
This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).
This guideline has been updated and replaced by NICE guideline NG246.
This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).
This guidance has been updated and replaced by NICE guideline NG203.
Asthma: diagnosis, monitoring and chronic asthma management (NG80)
This guideline has been updated and replaced by NICE guideline NG245.
TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
This medtech innovation briefing has been replaced by NICE healthtech guidance 716.
This medtech innovation briefing has been updated and replaced by NICE healthtech guidance 671.